Biodexa Pharmaceuticals Plc

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
ASSETS
Trade And Other Receivables $2.9m $3.7m $1.8m $3.6m $572k $1.0m $1.0m $637k $6.6m $3.8m
Goodwill $13.4m $22.9m $23.0m $0
Intangible Assets Other Than Goodwill $10.1m $10.1m $10.1m $0
Additional Financial Items
Current Tax Assets Current $1.4m $1.2m $2.0m $1.8m $1.2m $670k $846k $422k $573k $123k
Deferred Tax Assets $8.1m $9.5m $7.3m $9.0m $9.0m
Issued Capital $1.0m $1.0m $1.0m $1.0m $1.1m $1.1m $1.1m $6.3m $11.7m $14.1m
Trade And Other Current Payables $8.4m $8.0m $2.1m $4.5m $1.2m $1.1m $1.4m $1.2m $3.5m $2.6m
Trade And Other Current Receivables $2.4m $3.2m $1.3m $992k $572k $1.0m $1.0m $637k $6.6m $3.8m
Trade And Other Payables $8.4m $8.0m $2.1m $4.5m $1.2m $1.1m $1.4m $1.2m $3.5m $2.6m
Unused Tax Losses For Which No Deferred Tax Asset Recognised $2.7m $38.4m $40.4m $49.6m $63.2m $67.2m
Total Assets $56.7m $49.2m $20.4m $30.9m $9.8m $12.9m $5.5m $10.5m $14.8m $18.2m
LIABILITIES AND EQUITY
Increase Decrease Through Net Exchange Differences Deferred Tax Liability Asset $702k
Total Liabilities $11.0m $14.5m $3.5m $11.3m $3.1m $2.5m $2.4m $5.9m $6.5m $6.8m